UBS downgrades Allstate to Neutral, raises target to $261

1 min read | Published on 06 Jul 2026, 04:42 PM |Updated on 15 Jul 2026, 05:35 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

UBS analyst Brian Meredith downgraded Allstate from Buy to Neutral, raising the price target to $261 from $255. This follows adjustments from other analysts, including HSBC's downgrade to Hold with a $264 target, Barclays' raised target to $213, and Keefe, Bruyette & Woods' increase to $255.

*this image is generated using AI for illustrative purposes only.

Analysts have revised their outlooks on Allstate, with UBS downgrading the stock while several other firms adjusted price targets. UBS analyst Brian Meredith downgraded Allstate from Buy to Neutral and raised the price target from $255 to $261. The changes reflect shifting perspectives on the insurance provider's stock performance and valuation.

HSBC analyst Vikram Gandhi previously downgraded Allstate from Buy to Hold while raising the price target to $264 from $244. Barclays analyst Alex Scott maintained an Underweight rating and raised the price target to $213 from $203. Keefe, Bruyette & Woods analyst Meyer Shields maintained a Market Perform rating and raised the price target from $242 to $255. Cantor Fitzgerald analyst Ryan Tunis maintained a Neutral rating and raised the price target from $236 to $242.

The adjustments signal varied views on the company's future trajectory. UBS's downgrade accompanies a higher target, suggesting a more cautious stance on near-term momentum despite increased valuation expectations. HSBC's move similarly paired a rating cut with a target increase. Barclays and Keefe, Bruyette & Woods retained their bearish and neutral ratings respectively while acknowledging potential upside through higher targets.

Analyst	Rating	Previous Target	New Target
UBS (Brian Meredith)	Neutral	$255	$261
HSBC (Vikram Gandhi)	Hold	$244	$264
Barclays (Alex Scott)	Underweight	$203	$213
Keefe, Bruyette & Woods (Meyer Shields)	Market Perform	$242	$255
Cantor Fitzgerald (Ryan Tunis)	Neutral	$236	$242

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors are driving the divergence between UBS's downgrade and the raised price targets across multiple firms?

How might Allstate's near-term performance be impacted by the cautious stance adopted by analysts despite higher valuation expectations?

What broader market conditions could be influencing the varied outlooks from Barclays, HSBC, and Keefe, Bruyette & Woods?

Raymond James raises Allstate target to $300

0 min read | Published on 06 Jul 2026, 09:57 PM |Updated on 07 Jul 2026, 01:51 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Raymond James analyst C. Gregory Peters maintained a Strong Buy rating on Allstate and raised the price target to $300 from $260, signaling confidence in the insurer's valuation. This follows a separate update from Morgan Stanley, which maintained an Equal-Weight rating and raised its target to $240.

*this image is generated using AI for illustrative purposes only.

Raymond James analyst C. Gregory Peters has maintained a Strong Buy rating on Allstate (NYSE: ALL) and raised the price target to $300 from $260. The adjustment signals increased confidence in the insurer's valuation and potential for market outperformance. This development follows a recent revision by Morgan Stanley, which maintained an Equal-Weight rating with a price target of $240.

Rating and Target Details

The Strong Buy rating indicates that Allstate's stock is expected to significantly outperform the broader market. The increased price target reflects a more bullish stance on the company's future upside compared to previous estimates.